ConvaTec’s SCOPE Study Signals a Digital Edge in Ostomy Care

ConvaTec Group plc (GB:CTEC) announced an update on their ongoing clinical study.

Study Overview: ConvaTec Group’s recent study, formally titled “A Single-Time-Point, Observational Study to Evaluate Interrater Reliability of SACS 2.0 for the Assessment of Peristomal Skin Health in Ostomates,” aimed to check how consistently health professionals can rate peristomal skin health using the SACS 2.0 scale. The project, known as SCOPE (Single-Point Classification Observational Peristomal Evaluation), focuses on people living with ileostomies, colostomies, and urostomies and is important because reliable, standard scoring can support broader use of digital tools and more consistent care across markets.

Intervention/Treatment: This was not a drug or device trial in the classic sense. Instead, the “intervention” was the use of the SACS 2.0 classification system applied to images and in-person assessments of stoma and peristomal skin. The goal was to build a structured image dataset and compare digital image review with face-to-face assessments, helping ConvaTec refine digital wound and ostomy assessment solutions that could be layered onto its existing ostomy product portfolio.

Study Design: The study was observational rather than interventional, meaning participants simply received standard ostomy care while their skin condition was documented and rated. It used a case-control, forward-looking (prospective) structure, comparing different ostomy types without random assignment or treatment groups. There was no masking or blinding; clinicians knew what they were looking at. The main purpose was practical: to test how reliably different raters apply SACS 2.0 and to validate the use of photos for remote assessment versus in-person exams.

Study Timeline: The trial was first submitted on 24 September 2024, indicating when ConvaTec formally moved the project into the regulatory and public domain. It has now reached “Completed” status, with the latest update filed on 6 January 2026, signaling that core data collection and primary assessments are finished. No results have been posted yet, so investors should expect a lag between this update and any formal data release or follow-on product announcements tied to the findings.

Market Implications: For ConvaTec (GB:CTEC), this update reinforces its push into data-driven ostomy care and digital assessment, a trend that can extend product lifecycles and support premium pricing through better outcomes and remote monitoring. While the study will not deliver near-term revenue like a new device launch, reliable image-based scoring can underpin clinical decision support tools, hospital protocols, and value-based contracts, potentially boosting adoption of ConvaTec’s ostomy range. Competitors such as Coloplast and Hollister are also investing in digital and remote care tools, so positive read-through from SCOPE could help ConvaTec defend or grow share in advanced ostomy care and support a modestly positive bias in investor sentiment, particularly among long-term holders focused on recurring consumables and service-enabled growth. The study has been completed and recently updated, with further details available on the ClinicalTrials portal.